Findings

What do systematic reviews say?

670 questions · 686 findings · 338 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 349 · 50.9%GRADE not reported 70 · 10.2%Very low 75 · 10.9%Low 75 · 10.9%Moderate 87 · 12.7%High 30 · 4.4%

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 265 participants
Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Low

Benralizumab 100 mg vs placebo

Change in SGRQ total score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1433 participants
High

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1061 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Physical functioning component of health‐related quality of life, measured using various scales · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Moderate

DHEA vs placebo or control

QoL · Women in the peri‐ or postmenopausal phase

1 finding from 1 review

Dehydroepiandrosterone for women in the peri‐ or postmenopausal phase 2015 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 287 participants
Moderate

Hydroxyurea vs placebo

Health status and quality of life · people with sickle cell disease

1 finding from 1 review

Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 277 participants
Low

Noradrenaline reuptake inhibitors vs placebo

QoL · adults with schizophrenia

1 finding from 1 review

Selective noradrenaline reuptake inhibitors for schizophrenia 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 114 participants
Very low

Topical vitamin D derivative vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Puvatherapy vs placebo or no treatment

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etretinate vs placebo or no treatment

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etretinate with PUVA therapy as co‐intervention vs placebo with PUVA therapy

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Alitretinoin vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Etanercept vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ustekinumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Guselkumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Secukinumab vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic palmoplantar pustulosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dietary interventions vs placebo or other interventions

Parental or family quality of life, including measures of parental stress, anxiety or depression · infants with colic defined by recognised criteria

The review found no eligible studies for this question.

1 finding from 1 review

Dietary modifications for infantile colic 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chinese herbal medicines vs placebo

Vasomotor symptoms (vasomotor) · women with menopausal symptoms

1 finding from 1 review

Chinese herbal medicine for menopausal symptoms 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 256 participants
Low

Aclidinium bromide vs placebo

Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with stable chronic obstructive pulmonary disease

Aclidinium bromide leads to higher quality of life Number of patients who achieved at least 4 units… compared with placebo (high certainty).

1 finding from 1 review

Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes only
OR 1.49 [1.31, 1.7]
7 studies · 4420 participants
High